Teva ups dosage to $2.1bn as investors devour pharma bond
Israeli-US pharmaceutical company Teva has priced a $2.1bn bond package at the tighter end of initial price thoughts. Although Teva is still to sign a binding global settlement on its involvement in the opioid crisis, investors were happy to jump aboard a rare double-B issue yielding as much as 7%.
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: email@example.com